Document is current
Any future updates will be listed below
-
Authors
,
Muurling, Marijn http://orcid.org/0000-0001-9397-4602
de Boer, Casper
Kozak, Rouba
Religa, Dorota
Koychev, Ivan
Verheij, Herman
Nies, Vera J. M.
Duyndam, Alexander
Sood, Meemansa
Fröhlich, Holger
Hannesdottir, Kristin
Erdemli, Gul
Lucivero, Federica
Lancaster, Claire
Hinds, Chris
Stravopoulos, Thanos G.
Nikolopoulos, Spiros
Kompatsiaris, Ioannis
Manyakov, Nikolay V.
Owens, Andrew P.
Narayan, Vaibhav A.
Aarsland, Dag
Visser, Pieter Jelle
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative (806999)
- License Information
-
More Information
Article History
Received: 28 July 2020
Accepted: 11 April 2021
First Online: 23 April 2021
Declarations
:
: Not applicable.
: Not applicable.
: RK is an employee of Takeda Pharmaceuticals International Co. and holds stock options in both Pfizer Inc. and Takeda Pharmaceuticals International Co. IK receives consultancy fees from Mantrah Ltd. (mantrah.us), a digital technology company developing products for maintaining independence of people with cognitive impairment. CH is principal investigator on the Digital Biomarkers for Dementia project which is co-funded by Eli Lilly and Company and F. Hoffmann-La Roche Ltd. GE and KH are both currently employed by Novartis. NVM and VAN are employees of Janssen Pharmaceutica NV and may hold stock options or shares in the company. DA has received research support and/or honoraria from Astra-Zeneca, H. Lundbeck, Novartis Pharmaceuticals, Biogen, and GE Health and served as a paid consultant for H. Lundbeck, Eisai, Heptares, and Mentis Cura.
